These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29241378)

  • 1. Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes.
    Borchard G; Crommelin DJA
    Expert Opin Drug Deliv; 2018 Mar; 15(3):247-259. PubMed ID: 29241378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).
    Anderson J; Bell C; Bishop J; Capila I; Ganguly T; Glajch J; Iyer M; Kaundinya G; Lansing J; Pradines J; Prescott J; Cohen BA; Kantor D; Sachleben R
    J Neurol Sci; 2015 Dec; 359(1-2):24-34. PubMed ID: 26671082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.
    D Alessandro J; Garofalo K; Zhao G; Honan C; Duffner J; Capila I; Fier I; Kaundinya G; Kantor D; Ganguly T
    CNS Neurol Disord Drug Targets; 2017; 16(6):714-723. PubMed ID: 28240190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    Weinstock-Guttman B; Nair KV; Glajch JL; Ganguly TC; Kantor D
    J Neurol Sci; 2017 May; 376():255-259. PubMed ID: 28431621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.
    Grossman I; Kolitz S; Komlosh A; Zeskind B; Weinstein V; Laifenfeld D; Gilbert A; Bar-Ilan O; Fowler KD; Hasson T; Konya A; Wells-Knecht K; Loupe P; Melamed-Gal S; Molotsky T; Krispin R; Papir G; Sahly Y; Hayden MR
    Ann N Y Acad Sci; 2017 Nov; 1407(1):75-89. PubMed ID: 29168242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
    Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
    J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.
    Bourdette D; Hartung D
    JAMA Neurol; 2015 Dec; 72(12):1411-3. PubMed ID: 26457848
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
    Sørensen PS
    Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.
    Selmaj K; Barkhof F; Belova AN; Wolf C; van den Tweel ER; Oberyé JJ; Mulder R; Egging DF; Koper NP; Cohen JA;
    Mult Scler; 2017 Dec; 23(14):1909-1917. PubMed ID: 28090798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate.
    Greenberg B; Hall S; Grabner M; Balu S; Zhang X; Kantor D
    Curr Med Res Opin; 2020 Jul; 36(7):1167-1175. PubMed ID: 32329362
    [No Abstract]   [Full Text] [Related]  

  • 12. [A place of first-line drugs in treatment of multiple sclerosis].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Copaxone
    Arends RJ; Wang D; Buurman M; Luten J; Koper NP; Wolf C; Scheren M
    Pharmazie; 2019 Aug; 74(8):449-461. PubMed ID: 31526436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Moss BP; Cohen JA
    Mult Scler; 2019 Oct; 25(12):1560-1565. PubMed ID: 31074707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
    Hasson T; Kolitz S; Towfic F; Laifenfeld D; Bakshi S; Beriozkin O; Shacham-Abramson M; Timan B; Fowler KD; Birnberg T; Konya A; Komlosh A; Ladkani D; Hayden MR; Zeskind B; Grossman I
    J Neuroimmunol; 2016 Jan; 290():84-95. PubMed ID: 26711576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
    Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glatiramer acetate: A complex drug beyond biologics.
    Rocco P; Eberini I; Musazzi UM; Franzè S; Minghetti P
    Eur J Pharm Sci; 2019 May; 133():8-14. PubMed ID: 30902653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison.
    Chan A; Cutter G; Fox RJ; Xiao J; Lewin JB; Edwards MR
    J Comp Eff Res; 2017 Jun; 6(4):313-323. PubMed ID: 28350241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.